Sponsor Study ID:
A Phase 1b Open Label Study to Evaluate the Safety and Anti cancer Activity of Loncastuximab Tesirine in Combination with Other Anti cancer Agents in Patients with Relapsed or Refractory B cell Non Hodgkin Lymphoma (LOTIS 7)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polazutumab vedotin, or umbralisib, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)